Search
Use the filters to narrow by type of content
Looking for a Publication? Search the bibliography for: publications cost effectiveness model age related macular degeneration comparing macugen visudyne
… in the French healthcare setting by creating a decision model – likely the first study to compare screening … comparison to S100B in the current model. In addition to cost savings, using biomarker testing could free up resources … emergent imaging needs. Read the complete article here . Related Services Health Economics Staff Members Cheryl McDade …
… different approaches for developing a rigorous economic model structure for rare disease research that can help you … disease drugs? What are the key challenges to developing cost-effectiveness models? How do we overcome these HTA economic …
… to clinical trial data and provide analysis of non-normal cost and resource utilization data to demonstrate the cost and healthcare benefits of your new treatment. …
Using Real-World Evidence for Comparative Safety Studies Visit Our Real-World Evidence Services Page See the research: Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease Layton JB , …
Identifying an Appropriate Drug for Comparative Safety Research Antiepileptic Drugs in Pregnancy: Searching for a Reference Drug for Comparative Safety AV Margulis , AS Oberg, S Hernandez-Diaz. Poster presented at the 33rd International Conference on …
… HTA recommendations on health utility measurement for your cost-utility model? Many HTA agencies make specific statements about their … not available, use utilities from the UK may be used. Cost-Effectiveness Analysis Critical Appraisal Procedure (Státní …
… Publication Management and Medical Writing Publications are critical for the dissemination of your … and internal milestones is an integral part of the publications process. We develop a customized timeline for … who grant faster manuscript processing times and a reduced cost for Open Access publication. Our team can align …
… for Population Therapeutics Conference. Updated cost-utility and public health impact of recombinant zoster … J, Hicks K, Loukov D, Kaan I, Ng C, Regan J, Giannelos N. Cost-effectiveness and public health impact of recombinant zoster …
… and biotechnology products. She leads the development of cost-effectiveness, cost-utility, and cost-consequence models; … health, mental health, epilepsy, diabetic nephropathy, age-related macular degeneration, hospital-acquired …
… AstraZeneca, we evaluated cardiovascular safety endpoints related to the use of aclidinium. The study evaluated the …